Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Dumps 2.54 Million Doses Of Flu Vaccine, Losing $24.68 Million, Drawing Ire From Lawmakers

This article was originally published in PharmAsia News

Executive Summary

SEOUL - A ruling party lawmaker in South Korea claims the government's excess of flu vaccines has resulted in a loss of KRW 28.6 billion ($24.68 million) in government budgetary spending as it had to discard 2.54 million doses of the flu vaccines it secured from local vaccine maker Green Cross

You may also be interested in...



Korean Government Takes Precautionary Steps Against Pandemic Repeat

SEOUL - Hoping to avoid a recurrence of the influenza A/H1N1 pandemic from a year ago, South Korea's Ministry of Health and Welfare called on the country's senior citizens and the underprivileged to get free-of-charge flu vaccines beginning early October

Korean Government Takes Precautionary Steps Against Pandemic Repeat

SEOUL - Hoping to avoid a recurrence of the influenza A/H1N1 pandemic from a year ago, South Korea's Ministry of Health and Welfare called on the country's senior citizens and the underprivileged to get free-of-charge flu vaccines beginning early October

Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner

TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel